NewAmsterdam Pharma Company N.V. (NAMSW)
USD 14.85
(0.75%)
USD 14.85
(0.75%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 12.76 Million | 95.9 Million | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | 12.76 Million | 95.9 Million | - | - |
| Operating Expenses | 183.22 Million | 116.77 Million | 36.35 Million | 5.4 Million |
| Selling, General and Administrative Expenses | 29.77 Million | 18.21 Million | 5.27 Million | 1.38 Million |
| Research and Development Expenses | 159.42 Million | 81.01 Million | 25.45 Million | 4.04 Million |
| Other Expenses | - | - | - | - |
| Cost and Expenses | 183.22 Million | 116.77 Million | 36.35 Million | 5.4 Million |
| Operating Income | -165.73 Million | -3.32 Million | -30.73 Million | -5.42 Million |
| Interest Expense | 6.79 Million | - | - | - |
| Income Tax Expense | 27 Thousand | - | - | - |
| Earnings before Tax | -160.24 Million | -21.13 Million | -36.71 Million | -5.74 Million |
| Net Income | -176.93 Million | -21.13 Million | -36.71 Million | -5.74 Million |
| Earnings Per Share Basic | -2.15 | -1.11 | -3.34 | -1.15 |
| Earnings Per Share Diluted | -2.15 | -1.11 | -3.34 | -1.15 |
| Weighted Average Shares Outstanding | 82.16 Million | 18.96 Million | 17.75 Million | 17.75 Million |
| Weighted Average Shares Outstanding (Diluted) | 82.16 Million | 18.96 Million | 17.75 Million | 17.75 Million |
| Gross Margin | 1.00 | 1.00 | - | - |
| EBIT Margin | -12.98 | -0.03 | - | - |
| Profit Margin | -13.86 | -0.22 | - | - |
| EBITDA | -165.68 Million | -3.31 Million | -30.72 Million | -5.42 Million |
| Earnings Before Tax Margin | -12.99 | -0.03 | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 2.12 Million | 1.29 Million | 12.76 Million | 1.59 Million | 1.87 Million | 1.57 Million |
| Cost of Revenue | 17.73 Thousand | - | - | - | - | - |
| Gross Profit | 2.1 Million | 1.29 Million | 12.76 Million | 1.59 Million | 1.87 Million | 1.57 Million |
| Operating Expenses | 43.08 Million | 91.04 Million | 183.22 Million | 46.64 Million | 50.69 Million | 40.89 Million |
| Selling, General and Administrative Expenses | 15.37 Million | 13.39 Million | - | 10.16 Million | 10.92 Million | 9.03 Million |
| Research and Development Expenses | 35.82 Million | 39.31 Million | - | 35.72 Million | 38.92 Million | 31.47 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 43.08 Million | 91.04 Million | 183.22 Million | 46.64 Million | 50.69 Million | 40.89 Million |
| Operating Income | -49.07 Million | -51.41 Million | -165.73 Million | -44.29 Million | -47.96 Million | -38.93 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | - | 24.45 Thousand | 12.22 Thousand | 12.76 Thousand | - |
| Earnings before Tax | -36.41 Million | -86.89 Million | -160.24 Million | -42.52 Million | -46.07 Million | -35.08 Million |
| Net Income | -36.41 Million | -86.89 Million | -160.26 Million | -42.53 Million | -46.08 Million | -35.08 Million |
| Earnings Per Share Basic | -0.38 | -0.98 | - | -0.52 | -0.56 | -0.43 |
| Earnings Per Share Diluted | -0.38 | -0.98 | - | -0.52 | -0.56 | -0.43 |
| Weighted Average Shares Outstanding | 94.71 Million | 82.16 Million | 82.16 Million | 82.47 Million | 82.47 Million | 81.85 Million |
| Weighted Average Shares Outstanding (Diluted) | 94.71 Million | 82.16 Million | 82.16 Million | 82.47 Million | 82.47 Million | 81.85 Million |
| Gross Margin | 0.99 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| EBIT Margin | -23.06 | -39.59 | - | -27.78 | -25.55 | -24.73 |
| Profit Margin | -17.12 | -66.93 | -12.56 | -26.68 | -24.55 | -22.30 |
| EBITDA | -49.06 Million | -51.4 Million | - | -44.29 Million | -47.95 Million | -38.91 Million |
| Earnings Before Tax Margin | -23.07 | -39.60 | -12.99 | -27.78 | -25.55 | -24.74 |
ANSINDUS
IBG
TKCOF
SYNEX-R
ITNS
TEAMG